TriLink BioTechnologies® Extends Global Support of Covid-19 Vaccine Development into APAC Region with the Chula Vaccine Research Center (Chula VRC), Bangkok
August 02 2021 - 6:00PM
TriLink BioTechnologies (“TriLink”), a Maravai LifeSciences company
(Nasdaq: MRVI) and a leader in the production of nucleic acids for
research, diagnostics and therapeutics applications, has enabled
Chula Vaccine Research Center, at the Faculty of Medicine,
Chulalongkorn University (Chula VRC), Bangkok, to deliver an mRNA
Covid-19 vaccine that has been approved for an immediate FIH phase
1 clinical trial in Thailand. Building on its successful
partnerships in the development of effective mRNA Covid-19 vaccines
currently in use worldwide, TriLink was instrumental in the Chula
VRC mRNA Covid-19 vaccine’s mRNA manufacturing process development
and first clinical batch manufacturing of the drug substance.
TriLink will also continue to support manufacturing of the vaccine
through the use of
its
CleanCap® mRNA
capping technology for mRNA synthesis.
The ChulaCov19 mRNA Covid-19 Vaccine Development Program aims to
expand access to an mRNA Covid-19 vaccine in Thailand and other
low-to-middle-income countries (LMICs) in Asia. The vaccine is also
intended to provide a booster for people who have been vaccinated
with other previous vaccines to enhance their protection against
both the wild-type virus and new variants.
“TriLink is proud to have collaborated with ChulaVRC on this
critical Covid-19 vaccine, and we look forward to continuing to
support them through their clinical trials and manufacturing scale
up efforts,” said Brian Neel, Chief Operating Officer of TriLink
BioTechnologies. “We are committed to do our part to bring expanded
access to Covid-19 vaccines to populations in need across the globe
and continue to develop partnerships across the world in support of
this important work.”
Kiat Ruxrungtham, Director, ChulaVRC Covid-19 Vaccine
Development Program, stated: “It is our great pleasure to partner
with the TriLink team in fighting this pandemic. This collaboration
will not only help us combat Covid-19, it will also support our
readiness to make vaccines against any new variants of concern or
any pandemic to come in a much timelier manner, for LMICs in
particular.”
The TriLink-ChulaVRC partnership was made possible through Dr.
Drew Weissman, MD, PhD, an infectious disease expert at University
of Pennsylvania Medicine and one of the primary researchers
responsible for breakthrough components of other mRNA-based
vaccines and therapeutics being manufactured and used globally.
“Our collaboration with Professor Kiat at Chula VRC is making
mRNA vaccine technology accessible to underserved countries in this
region to fight the pandemic. This strong partnership will also
extend beyond Covid-19 to other needed vaccines, for both
infectious diseases and other non-communicable diseases in the near
future,” commented Dr. Weissman.
In addition to Chula VRC and its relationships in the United
States and EMEA, TriLink is currently in discussions to supply
CleanCap and CleanCap mRNA to other organizations within China,
Japan and other nations across the Asia-Pacific region who are
seeking to develop successful mRNA Covid-19 vaccines.
TriLink’s Brian Neel further added that, “As pioneering
manufacturers of GMP-grade mRNA, TriLink has been instrumental in
the fight against Covid-19. We stand at the ready with the
experience, expertise, and scalable resources to empower partners
in every geography. As we extend our services, we believe we can
help stem the further impact of this pandemic.”
About TriLink BioTechnologies
TriLink BioTechnologies, part of Maravai LifeSciences, is a CDMO
helping life science leaders and innovators overcome challenges in
the synthesis and scale-up of nucleic acids, NTPs and mRNA capping
analogs with scale-up expertise and unique mRNA production
capabilities, including its proprietary CleanCap® mRNA capping
technology. TriLink continues to expand its cGMP and general
manufacturing capacity at its new global headquarters to support
mRNA, oligonucleotide & plasmid therapeutic, vaccine and
diagnostic
customers. www.trilinkbiotech.com
About Maravai LifeSciences
Maravai is a leading life sciences company providing critical
products to enable the development of drug therapies, diagnostics,
novel vaccines and support research on human diseases. Maravai's
companies are leaders in providing products and services in the
fields of nucleic acid synthesis, bioprocess impurity detection and
analysis, and protein labeling and detection to many of the world's
leading biopharmaceutical, vaccine, diagnostics, and cell and gene
therapy companies.
For more information about Maravai LifeSciences,
visit www.maravai.com.
Forward-looking Statements
This press release contains “forward-looking statements” within
the meaning of the safe harbor provisions of the U.S. Private
Securities Litigation Reform Act of 1995. Investors are cautioned
that statements in this press release which are not strictly
historical statements constitute forward-looking statements,
including, without limitation, statements regarding Chula VRC’s
continued use of CleanCap, the expansion of access to mRNA COVID-19
vaccines and their ability to enhance protection against both the
wild-type virus and new variants, our ability to develop new
partnerships, the ability of our partners to address new pandemics
in a timely manner or develop new vaccines to address both
infectious disease and other non-communicable diseases in the near
future, and our ability to help stem the further impact of the
COVID-19 pandemic, constitute forward-looking statements and are
identified by words like “aim,” “believe,” “expect,” “may,” “will,”
“should,” “seek,” “anticipate,” or “could” and similar expressions.
Such forward-looking statements are subject to a number of risks
and uncertainties that could cause actual results to differ
materially from those anticipated, including, without limitation
and uncertainties related to the level of demand for our products
and services, continued validation of the safety and effectiveness
of our technology, new scientific developments and competition from
other products. These and other risks and uncertainties are
described in greater detail in the section entitled “Risk Factors”
in our Annual Report on Form 10-K for the year ended December 31,
2020, as well as other documents on file with the Securities and
Exchange Commission. Actual results may differ materially from
those contemplated by these forward-looking statements, and
therefore you should not rely upon them. These forward-looking
statements reflect our current views and we do not undertake to
update any of these forward-looking statements to reflect a change
in its views or events or circumstances that occur after the date
hereof except as required by law.
Contact Information:
Maravai LifeSciences
Media Contact: Sara Michelmore
MacDougall
+1 781-235-3060
maravai@macbiocom.com
Investor Contact: Deb Hart
Maravai LifeSciences
+ 1 858-988-5917
ir@maravai.com
Chula VRC
Kiat Ruxrungtham,
Professor of Medicine,
Chula VRC, Chulalongkorn University,
Bangkok, Thailand
kiat.r@chula.ac.th
Maravai LifeSciences (NASDAQ:MRVI)
Historical Stock Chart
From Aug 2024 to Sep 2024
Maravai LifeSciences (NASDAQ:MRVI)
Historical Stock Chart
From Sep 2023 to Sep 2024